SynthesisJournal of veterinary pharmacology and therapeutics2026
What Do We Know About Cyclooxygenases Expression in the Lower Urinary Tract of Dogs and Cats? A Systematic Review.
Synthesis in Journal of veterinary pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclooxygenases (COX-1 and COX-2) are key enzymes in the biosynthesis of prostanoids, which mediate physiological functions, inflammation, and the process of carcinogenesis. In dogs and cats, lower urinary tract diseases are prevalent and often complex, requiring targeted therapeutic interventions. Although the role of cyclooxygenases is well established in humans, their expression profile in dogs and cats remains underexplored. This systematic review aimed to consolidate the available knowledge regarding the expression of COX-1 and COX-2 in the lower urinary tract tissues of dogs and cats, highlighting pathological implications and gaps in the literature. A total of 28 original studies were included in this review, which employed methodologies such as immunohistochemistry (IHC), Western blotting (WB), in situ hybridization (ISH), RNA sequencing, and ELISA. The urinary bladder was the most frequently analyzed tissue, followed by the urethra. COX-2 expression was predominantly elevated in tissues with inflammation or neoplasia, whereas COX-1 exhibited a constitutive expression pattern in normal tissues. In cats with feline idiopathic cystitis (FIC), COX-2 expression was significantly elevated in the urethral mucosa. In cases of transitional cell carcinoma (TCC), COX-2 expression varied substantially. The consistent expression of COX-1 in both normal and altered tissues suggested a homeostatic role. Despite the potential of COX-2 as a therapeutic target and prognostic marker, methodological heterogeneity, small sample sizes, and the lack of standardized criteria limit the comparability of findings. This review underscores the need for well-designed studies and standardized approaches to better understand the role of COX enzymes in the uropathology of small animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.